SOX2 and non-small cell lung carcinoma: We used the well-characterizedPC9 cell model of EGFR-mutant NSCLC to transfect siRNAs against SOX2 (the same duplexvalidated by rescue in Figure 5C) or control,followed by continuous exposure to 1.0 μM erlotinib (Figure 5E).